Valles J, Artigas R, Bertolotti M, Crea A, Muller F, Paredes I, Capriati A
Menarini Research, Clinical Department, Badalona, Spain.
Methods Find Exp Clin Pharmacol. 2006 Jun;28 Suppl A:13-9.
Dexketoprofen trometamol, a high water-soluble salt of the active enantiomer of rac-ketoprofen, is a nonsteroidal antiinflammatory drug (NSAID) widely used for pain relief. This study was conducted to determine the pharmacokinetics of this analgesic agent in elderly subjects and to compare them with young volunteers following single and repeated oral doses. Twelve healthy young and 12 elderly subjects received 25 mg oral dexketo- profen (equivalent to 37 mg of its tromethamine salt) as a single dose (day 1) and 3-day repeated doses (1 dose every 8 h for a total of 10 doses). Serial concentrations of dexketoprofen were determined in plasma and urine by a reverse-phase HPLC/ultraviolet procedure over 24 h on day 1 and after the last 10th repeated t.i.d. dose. Compared to young subjects, elderly subjects showed significant increases in AUC and t1/2,z and decreases in CL/F following single and repeated doses. After single dosing, the corresponding mean +/- SD values were 5106.6 +/- 1873.0 vs. 3605.4 +/- 897.9 ng.h/ml (p = 0.015); 1.59 +/- 0.40 vs. 1.12 +/- 0.20 h (p < 0.001); and 1.11 +/- 0.29 vs. 1.63 +/- 0.36 ml/min/kg (p < 0.001). After the repeated dose, AUC, t1/2,z and CL/F averaged 5067.8 +/- 1373.4 vs. 3194.4 +/- 694.3 ng.h/ml (p < 0.001); 1.65 +/- 0.44 vs. 1.11 +/- 0.29 h (p < 0.005); and 1.12 +/- 0.23 vs. 1.87 +/- 0.42 ml/min/kg (p < 0.001). Median tmax was 0.5 h. Cumulative excretions in urine up to 24 h of unbound, conjugated and total dexketoprofen were similar among the groups. These results suggest that dexketoprofen elimination is reduced in the elderly. Although no drug accumulation in plasma was observed after single and repeated dosing, the renal function decline in elderly patients calls for a cautious dose-adjustment in this population.
右酮洛芬氨丁三醇是消旋酮洛芬活性对映体的一种高水溶性盐,是一种广泛用于缓解疼痛的非甾体抗炎药(NSAID)。本研究旨在确定该镇痛药在老年受试者中的药代动力学,并与年轻志愿者单次和重复口服给药后的药代动力学进行比较。12名健康年轻受试者和12名老年受试者接受了25mg口服右酮洛芬(相当于其氨丁三醇盐37mg)作为单次剂量(第1天)和3天重复剂量(每8小时1剂,共10剂)。在第1天24小时内以及最后第10次重复每日3次给药后,通过反相HPLC/紫外法测定血浆和尿液中右酮洛芬的系列浓度。与年轻受试者相比,老年受试者单次和重复给药后AUC和t1/2,z显著增加,CL/F降低。单次给药后,相应的平均值±标准差分别为5106.6±1873.0与3605.4±897.9ng·h/ml(p = 0.015);1.59±0.40与1.12±0.20小时(p < 0.001);以及1.11±0.29与1.63±0.36ml/min/kg(p < 0.001)。重复给药后,AUC、t1/2,z和CL/F的平均值分别为5067.8±1373.4与3194.4±694.3ng·h/ml(p < 0.001);1.65±0.44与1.11±0.29小时(p < 0.005);以及1.12±0.23与1.87±0.42ml/min/kg(p < 0.001)。tmax中位数为0.5小时。各年龄组在24小时内未结合、结合和总右酮洛芬的尿液累积排泄量相似。这些结果表明老年受试者中右酮洛芬的消除减少。虽然单次和重复给药后未观察到血浆中药物蓄积,但老年患者肾功能下降要求在该人群中谨慎调整剂量。